SCD and acute myeloid leukemia: As predicted, we then observed synergy between SCD inhibition and doxorubicin in vitro, and the combination of SSI-4 with conventional AML chemotherapy in vivo significantly prolonged survival in the AML model that demonstrated decreased sensitivity to SCD inhibition alone.